文章：

非小细胞肺癌中的腺苷能通路

The Adenosinergic Pathway in Non-Small Cell Lung Cancer

原文发布日期：13 September 2024

DOI: 10.3390/cancers16183142

类型: Article

开放获取: 是

英文摘要：

Immune checkpoint inhibitors (ICIs) targeting PD-(L)1 and CTLA-4 have revolutionized the systemic treatment of non-small cell lung cancer (NSCLC), achieving impressive results. However, long-term clinical benefits are only seen in a minority of patients. Extensive research is being conducted on novel potential immune checkpoints and the mechanisms underlying ICI resistance. The tumor microenvironment (TME) plays a critical role in modulating the immune response and influencing the efficacy of ICIs. The adenosinergic pathway and extracellular adenosine (eADO) are potential targets to improve the response to ICIs in NSCLC patients. First, this review delves into the adenosinergic pathway and the impact of adenosine within the TME. Second, we provide an overview of relevant preclinical and clinical data on molecules targeting this pathway, particularly focusing on NSCLC.

摘要翻译： 

靶向PD-(L)1和CTLA-4的免疫检查点抑制剂（ICIs）已彻底改变了非小细胞肺癌（NSCLC）的系统性治疗，取得了令人瞩目的成果。然而，仅少数患者能获得长期临床获益。目前针对新型潜在免疫检查点及ICI耐药机制的研究正在广泛开展。肿瘤微环境（TME）在调节免疫反应及影响ICI疗效方面起着关键作用。腺苷能通路与细胞外腺苷（eADO）是改善NSCLC患者对ICI应答的潜在靶点。本文首先深入探讨腺苷能通路及腺苷在TME中的作用机制，其次系统综述靶向该通路分子的相关临床前与临床研究数据，并特别聚焦于NSCLC领域。

原文链接：

The Adenosinergic Pathway in Non-Small Cell Lung Cancer